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Introduction
Hepatitis C virus (HCV) infection is a major global health problem, infecting more than 170 million people worldwide 1 . Some newly infected patients recover spontaneously but the majority progress to chronic infection, so that HCV infection is now the leading cause of cirrhosis, hepatocellular cancer and liver transplantation in the Western world 2 . Persisting strong CD8+ T-cell responses are observed in the majority with resolved HCV infection 3 but the role of host factors in viral clearance and disease progression remains unclear. There is some evidence that host genetic factors are implicated in the outcome following HCV infection 4 . Specific HLA haplotypes have been associated with a significantly increased likelihood of viral clearance, including the HLA-DRB1*1101-DQB1*0301, DRB1*1104-DQB1*0301 and DRB1*0401-DQB1*0301 haplotypes [4] [5] [6] [7] . In addition recent data suggests that inherited variation in the killer inhibitory receptor genes may play a significant role in determining the host response to HCV infection 8 . Other host factors associated with disease progression in chronic HCV include male sex, age at infection, excessive alcohol use, total cholesterol level and insulin resistance 9 . In addition there is now considerable accumulating evidence to suggest a relationship between hepatitis C virus and lipid metabolism 10 . During the early stages of acute HCV infection in chimpanzees host genes involved in lipid metabolism are differentially regulated 11 . In patients with chronic HCV serum cholesterol is significantly lower than in appropriately matched controls 12 , particularly in HCV genotype 3 infection 13 14 and this metabolic effect is fully reversible after successful HCV eradication 15 The association of HCV infection with hypocholesterolaemia has been confirmed in HIV-infected patients 16 and in patients with porphyria cutanea tarda 17 . In many studies the hypocholesterolaemia has been associated with a decrease in apolipoprotein B (ApoB) in comparison with healthy controls 12 17 18 and ApoB levels negatively correlate with hepatic steatosis and viral load 18 . Furthermore, HCV viral load can be reduced by H.E.L.P. apheresis, which is an established and approved therapy for hypercholesterolaemia 19 . HCV RNA containing particles are consistently found in the low-density fractions of serum and this fraction has been shown to be highly infectious 20 . Further characterisation of these low density HCV RNA containing particles (lipo-viral particles (LVP)) has shown they efficiently bind and enter hepatocyte cell-lines, upregulation of the low density lipoprotein receptor (LDLr) increases their internalisation and binding of HCV-LVP can be blocked by anti-ApoB and antiapolipoprotein E (ApoE) 21 22 . This is consistent with other studies showing that endocytosis of HCV can be mediated by LDLr 23 24 . LDLr, a candidate receptor for HCV, normally transports 2 different classes of cholesterol containing lipoprotein particles into cells: LDL, which contains a single copy of ApoB-100 and VLDL, which contains multiple copies of ApoE. Recent studies with retrovirus/HCV pseudovirus particles 25 suggest that attachment to hepatocytes is via the scavenger receptor protein, SR-B1, with entry into the cell via a co-receptor CD-81 dependent pathway 26 27 . SR-B1, which is expressed primarily in the liver, is a key component in the reverse cholesterol transport pathway, and recognizes a broad variety of lipoprotein ligands, including HDL, LDL, VLDL and oxidised LDL [28] [29] [30] . Apolipoprotein E, a ligand for both LDLr and SR-B1, is a polymorphic protein arising from 3 alleles at a single gene locus. The three major isoforms, Apo-ε2, Apo-ε3, and Apo-ε4, differ from one another by single amino acid substitutions, a change which has profound functional consequences at both cellular and molecular levels. Apo-ε3 seems to be the wild type isoform with normal function, while Apo-ε2 binds poorly to LDLr and Apo-ε4 induces a down-regulation of LDLr 31 . A previous study of APOE gene polymorphisms in HCV infection suggested decreased severity of liver disease in patients with the E4 allele 32 . As apolipoprotein E is a ligand for the HCV receptor candidates LDLr and SR-B1 and in view of the considerable evidence suggesting that cholesterol and fatty acid pathways may play a role in HCV replication and infection, the aim of this study was to determine whether the common functional polymorphisms of the APOE gene can influence the clinical outcome of HCV infection.
Patients and Methods
Patients 5 mls of whole blood was obtained from 420 Caucasian HCV antibody positive patients recruited from two centres, the joint hepatitis clinic of the Freeman Hospital, Newcastle-upon-Tyne, England (n=241) and St. James's Hospital, Dublin, Ireland (n=179) 33 . 5 mls of whole blood was also collected from 288 healthy adult volunteers (controls) to assess the apolipoprotein E genotype distribution in the healthy population 34 . HCV viral RNA was tested in all HCV antibody positive patients using the Amplicor reverse transcriptase polymerase chain reaction (PCR) assay (Roche). 312 patients were HCV RNA positive on at least two occasions indicating a persistent or chronic infection, whereas 108 patients were HCV RNA negative on at least two occasions, indicating spontaneously resolved infection. Liver biopsies were available on 209 patients with evidence of chronic infection. Each biopsy was scored by a single observer, Prof A.D. Burt, using the Ishak scoring system 35 . Biopsies were graded for necroinflammation on a scale of 0-16 and fibrosis on a scale of 0-6 [fibrosis stage of 5 or 6 indicated severe disease, 2-4 moderate disease and 0 or 1 mild disease]. An estimate of the rate of fibrosis was made on 178 of these patients. A date of infection was either estimated in intravenous drug users (IVDU) as the date when IVDU started, or was calculated as the date of exposure to infected blood or the date of a one off/short period of IVDU. The Ishak stage of fibrosis was divided by the time in years from date of infection to first biopsy to give a calculation of the rate of fibrosis. Rapid progression was identified as patients progressing to cirrhosis within 20yrs (a rate of fibrosis >0.25/yr). In this subgroup of patients, data on alcohol use, age at biopsy, sex and mode of infection were also collected; all data and results were entered into a Microsoft® Access TM database. Apolipoprotein E genotyping Genomic DNA was isolated from 2mls of whole blood using QIAamp® midi kits TM (Quiagen® Ltd, Crawley, UK). A 227bp product of the APOE gene was amplified using a pair of sequence specific primers in a standard PCR reaction 36 . Briefly; approximately 100ng of DNA was amplified in a 50µl reaction mix containing 2.5µl of 100% DMSO, 1.5mM MgCl 2 , 10mM tris-HCl, 50mM KCL, 0.5µM of each primer , 200µM of each nucleotide and 2.5U of Taq polymerase (ABGENE®, Epsom, Surrey, UK). Amplification conditions were as follows: 2 minutes at 95 0 C and then 40 cycles of 2 minutes at 95 0 C, 2 minutes at 65 0 C and 2 minutes at 72 0 C, and a final extension for 5 minutes at 72 0 C. All PCR batches included a water (DNA free) negative control and samples of known genotype. All genotypes were assigned by two independent investigators and any ambiguous genotypes were repeated. The 227-bp product was sub-aliquoted into duplicate reaction tubes and subject to digestion with two different restriction endonucleases AflIII and HaeI1; digestions were performed with 25U of each enzyme at room temperature for a minimum of 3 hours. The resulting restriction fragments were separated on 3% agarose gels and the bands were visualised using ethidium bromide staining on a UV trans-illuminator and documented on an AlphaImager TM 2200 Documentation and Analysis System (AlphaInnotech Corp., USA). AflIII digests the PCR amplicons of the APOE*2 and E3 alleles only creating bands of 117bp and 50bp (amplicons of E4 do not digest leaving the 227 bp amplicon intact). HaeII digests the E3 and E4 amplicons only resulting in bands of 195bp and 32bp (amplicons of the E2 allele are not digested leaving an intact 227bp amplicon). Thus, by comparing the restriction patterns for the two digests on every sample we can assign composite genotypes for
E2,E2: E2,E3: E3,E3: E2,E4; E3,E4 and E4,E4

Statistical Analysis
Genotype and allele distribution were compared using Stata. As the E3 allele is associated with normal APOE activity the risk for the common (wild type) genotype E3,E3 was fixed (at 1) and risk for all other genotypes are reported relative to this. In the whole HCV antibody positive cohort (n=420) the following comparisons of allele and genotype distribution were made:
• Control group (n = 288) versus HCV exposed (HCV antibody positive) population.
• Chronic HCV infection (n = 312) versus spontaneously resolved (cleared) infection (n = 108). In the subgroup with chronic HCV infection whose liver biopsies were scored by a single observer the following comparisons of allele and genotype distribution were made:
• Severe liver disease versus mild/moderate chronic hepatitis (n=209)
• Slow fibrosis progression versus rapid fibrosis progression (n=178)
Risk is reported as Genotype Relative Risk (GRR) for comparison of genotype distribution and Odds Ratio (O.R.) for comparison of allele distribution with 95% Confidence Intervals (C.I.). Multivariate binary logistic regression was used to assess independent variables including sex, alcohol usage and age of infection in relation to APOE status in HCV antibody positive patients. All additional computations were performed using SPSS-10 for windows.
Results
Comparing all patients versus healthy controls there was a significantly lower frequency of the E2,E2 genotype in the diseased population (χ 2 = 7.34, p=0.0067). (table 2) 
E4,E4
3 (1%) 1 (1%) 0.76 (0.77 -7.42) ns APOE*2 was the only independent predictor of viral clearance in a multivariate logistic regression model. No other significant associations were found comparing patients and controls, or comparing those with chronic versus those with resolved HCV infection. In addition there was no significant association between APOE genotype or APOE alleles and the clinical phenotypes defined by severe inflammation (Ishak grade >8, n = 37), severe fibrosis (Ishak stage 5 and 6, n = 45) or fast fibrosis (rate of fibrosis ≥0.25/year, n = 60).
Discussion
Apolipoprotein E plays an important role in the transport of cholesterol and other lipids among cells of various tissues. Three major isoforms, encoded by three common alleles at the APOE locus, have different binding affinities for the Apo E receptors. The E2 allele is associated with defective binding to LDLr and the E4 allele with down regulation of LDLr compared to E3 31 . In this study APOE*2 and APOE4 alleles were both associated with an increased likelihood of viral clearance and, interestingly, there were no HCV antibody positive patients with the APOE E2,E2 genotype, though this is relatively rare in healthy controls (0.5-2%) 37 . A previous investigation of the influence of APOE polymorphism and outcome of HCV infection 32 suggested that the APOE*4 allele protected against severe liver disease. Our results did not confirm this finding but did suggest that this allele may also be associated with a reduced risk of viral persistence. However it is probable that neither this nor the earlier study is adequately powered to look at subtle effects of the Apo-ε4 isoform on disease progression. This latter comment is especially true when other factors associated with disease progression which may vary between cohorts are considered 9 . Another small study has suggested that heterozygosity for the APOE*4 allele might be associated with better histological outcome in recurrent HCV infection in the liver transplantation setting 38 , but this situation is complicated by possible differences in donor/recipient APOE alleles. It is also of interest that chronic HCV is associated with cognitive dysfunction and CNS infection 39 and a recent study has demonstrated an association between APOE*4 and neuro-psychiatric symptoms during interferon alpha treatment for chronic HCV 40 . The association found between the E2 allele and viral clearance is intriguing as this allele binds poorly to LDLr 31 . It is plausible that such defective binding could result in poor uptake of HCV lipo-viral particles into the hepatocyte with a resultant decrease in replication of the virus, thus altering the balance between virus replication and the immune response and favouring clearance of the virus before chronic infection can be established. This is supported by the lack of E2,E2 genotype among patients who are HCV antibody positive, suggesting that the E2,E2 genotype (0.5-2% of healthy controls 37 ) may confer relative resistance to establishing HCV infection in exposed individuals. This could be somewhat analogous to the role played by the chemokine receptor-5 delta 32 mutation, which leads to defective uptake of the HIV virion and therefore resistance to HIV/AIDS 41 . In the latter case, homozygotes for the delta 32 mutation exhibit a strong, although incomplete, resistance to HIV infection, whereas heterozygotes display delayed progression to acquired immunodeficiency syndrome. Conversely the results reported here may indicate an association between the APOE*3 allele and persistence of hepatitis C virus. This would fit a model whereby APOE*3 binds to receptors with high affinity and is associated with normal serum cholesterol and triglyceride levels.
In conclusion this study suggests that common genetic variations at the APOE locus influence the outcome of HCV infection with the APO*E2 and APO*E4 alleles favouring viral clearance. We hypothesise that ApoE2, which binds poorly with its receptors, may be associated with resistance to HCV infection, via defective uptake of HCV lipo-viral particles by the candidate receptors LDLr and SR-B1. Further investigations are needed, especially in individuals who are likely to have been repeatedly exposed to HCV but remain anti-HCV antibody negative 42 . Although the inability to replicate the results of case-control studies has led to scepticism about their value 43 , our findings are both biologically plausible and statistically significant. If our findings are confirmed in a validation study, the function of Apolipoprotein E in assembly, processing and removal of plasma lipoproteins and its interaction with HCV could be considered in the development of novel therapeutic strategies.
